Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Salt Lake City, Utah

Phase 3 cancer trials in Salt Lake City, UT

53 Phase 3 cancer studies are recruiting participants at sites in Salt Lake City as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Salt Lake City at a glance

Breast cancer studies recruiting in Salt Lake City

Basic details from each study's public record (the 30 most recently updated of 53). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Utah, Huntsman Cancer Institute ( Site 0056)
    Registry record
    NCT06841354 · updated
  2. Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Utah
    Study site
    Huntsman Cancer Institute at University of Utah
    Registry record
    NCT07166042 · updated
  3. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT06982521 · updated
  4. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT05633654 · updated
  5. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    Huntsman Cancer Institute/University of Utah · University of Utah Sugarhouse Health Center
    Registry record
    NCT05879926 · updated
  6. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Huntsman Cancer Hospital at the University of Utah
    Registry record
    NCT06790693 · updated
  7. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Utah Cancer Specialists
    Registry record
    NCT07174336 · updated
  8. BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Utah Cancer Specialists Cancer Center
    Registry record
    NCT07492641 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Lung cancer studies recruiting in Salt Lake City

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  2. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Huntsman Cancer Institute
    Registry record
    NCT07063745 · updated
  3. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Huntsman Cancer Institute ( Site 0042)
    Registry record
    NCT06312137 · updated
  4. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Utah Cancer Specialists
    Registry record
    NCT06712316 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Prostate cancer studies recruiting in Salt Lake City

  1. Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    LDS Hospital
    Registry record
    NCT06931340 · updated
  2. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Utah Cancer Specialists
    Registry record
    NCT07164443 · updated
  3. Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    NRG Oncology
    Study sites
    Huntsman Cancer Institute/University of Utah · LDS Hospital · University of Utah Sugarhouse Health Center
    Registry record
    NCT05946213 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Melanoma studies recruiting in Salt Lake City

  1. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    University of Utah Huntsman Cancer Institute
    Registry record
    NCT06246916 · updated
  2. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Lymphoma studies recruiting in Salt Lake City

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT06337318 · updated
  2. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Study site
    Huntsman Cancer Insititute, University of Utah
    Registry record
    NCT05303519 · updated
  3. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT06724237 · updated
  4. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT04269902 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Huntsman Cancer Institute/University of Utah · Primary Children's Hospital
    Registry record
    NCT05675410 · updated
  6. A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Huntsman Cancer Institute - Oncology Division
    Registry record
    NCT06091254 · updated
  7. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Intermountain Healthcare
    Registry record
    NCT07188558 · updated
  8. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT03150693 · updated
  9. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT05976763 · updated
  10. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Huntsman Cancer Institute/University of Utah
    Registry record
    NCT07215910 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Salt Lake City

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US053
    Registry record
    NCT07522073 · updated
  2. A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Utah Cancer Specialists
    Registry record
    NCT07409272 · updated
  3. Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Huntsman Cancer Institute, University of Utah
    Registry record
    NCT06943755 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Salt Lake City, UT on ClinicalTrials.gov.

Ask about studies near Salt Lake City

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call